Distribution and Progression of Visual Field Defects With Binocular Vision in Glaucoma.
Hashimoto Shigeki, Matsumoto Chota, Eura Mariko, Okuyama Sachiko, Nomoto Hiroki, Tanabe Fumi, Kayazawa Tomoyasu, Iwase Aiko, Shimomura Yoshikazu
AI Summary
This study found binocular glaucoma defects often appear near Mariotte blind spots and bitemporal areas, progressing differently than monocular defects, which is crucial for assessing real-world vision.
Abstract
Purpose
To evaluate the distribution and progression of glaucomatous visual field (VF) defects with binocular vision.
Patients and methods: Subjects were 167 patients (average age, 67±10.7 y) with glaucoma who received the Humphrey 24-2 VF test (SITA-Standard) for the 2 eyes. Using the Best Location Algorithm, patient's binocular integrated VF (IVF) was calculated from their Humphrey 24-2 results. Of 167, 77 subjects (average age, 68±11.0 y) also underwent monocular/binocular Humphrey Esterman tests. Patient's stage of glaucomatous VF loss was classified by the Esterman Disability Score for each test, and the distribution and progression of the defects with binocular vision was evaluated for each stage. The frequencies of the defects in the upper and lower halves of the VF were also investigated.
Results
With the IVF, the glaucomatous VF defects were most frequently found around the Mariotte blind spots and the Bjerrum areas and extended to the periphery. With the binocular Humphrey Esterman VF, the defects were most frequently found around the bitemporal and Bjerrum areas. The IVF results showed 31%, 49%, and 20% of the patients with the earliest glaucoma having defects in the upper, lower, and both halves of the VF, respectively.
Conclusions
Glaucomatous VF defects with binocular vision were frequently found at the Mariotte blind spots in the central VF and around the bitemporal areas in the periphery. They appeared to have distributions and progression different from those of the defects with monocular vision previously reported.
MeSH Terms
Shields Classification
Key Concepts5
In 167 patients (average age, 67±10.7 years) with glaucoma, glaucomatous visual field (VF) defects with binocular vision, calculated using the Best Location Algorithm from Humphrey 24-2 VF test results, were most frequently found around the Mariotte blind spots and the Bjerrum areas and extended to the periphery.
In 77 subjects (average age, 68±11.0 years) with glaucoma, binocular Humphrey Esterman VF tests showed that defects were most frequently found around the bitemporal and Bjerrum areas.
In 167 patients with glaucoma, integrated visual field (IVF) results showed that among patients with the earliest glaucoma, 31% had defects in the upper half of the visual field, 49% had defects in the lower half, and 20% had defects in both halves of the visual field.
The study evaluated the distribution and progression of glaucomatous visual field (VF) defects with binocular vision in 167 patients (average age, 67±10.7 years) with glaucoma using the Humphrey 24-2 VF test and the Best Location Algorithm to calculate binocular integrated VF (IVF).
In 77 of 167 patients with glaucoma, monocular/binocular Humphrey Esterman tests were performed to classify the stage of glaucomatous VF loss by the Esterman Disability Score and evaluate the distribution and progression of defects with binocular vision for each stage.
Related Articles5
Archetypal analysis quantifies changes in patterns of visual field loss in eyes with acute non-arteritic anterior ischaemic optic neuropathy.
Observational StudyFactors associated with vision loss in idiopathic intracranial hypertension patients with severe papilledema.
Cohort StudyComparative Analysis of 24-2C, 24-2, and 10-2 Visual Field Tests for Detecting Mild-Stage Glaucoma With Central Visual field Defects.
Observational StudyMicroperimetry Characteristics of Regions With a Truly Nonresponding Location: Implications for Atrophic Age-Related Macular Degeneration.
Observational StudyValidation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.